ArticleInvestigational new drugs2023

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.